Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSI1-C-terminus decoy peptide is a therapeutic peptide designed to disrupt the interaction between the RNA-binding protein Musashi1 (MSI1) and Argonaute2 (AGO2). In glioblastoma multiforme (GBM), MSI1 translocates to the cytoplasm under stress conditions and recruits AGO2 to form a complex that modulates mRNA stability, promoting tumor cell proliferation and survival. This decoy peptide mimics the C-terminal domain of MSI1, which is the site of direct binding to AGO2, thereby competitively inhibiting the formation of the MSI1/AGO2 complex. Preclinical studies in orthotopic mouse models of GBM have shown that delivery of this peptide effectively reduces stress-induced tumor progression, suggesting a novel peptide-based therapeutic strategy against refractory malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MSI1-C-terminus decoy peptide.